There are 2789 resources available
1258P - MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study
Presenter: Hélène Babey
Session: ePoster Display
1259P - Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Presenter: Xiuning Le
Session: ePoster Display
1260P - Clinical outcomes of patients with BRAF<sup>v</sup>⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice
Presenter: Barbara Melosky
Session: ePoster Display
1261P - Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
Presenter: Jade van Berge Henegouwen
Session: ePoster Display
1262P - ROS1 resistance mutations and co-occurring genetic alterations to the ROS1 protein-tyrosine kinase inhibitors (crizotinib) in lung cancer
Presenter: Yuqing Weng
Session: ePoster Display
1265P - Combined detection of tumor markers and ctDNA in cerebrospinal fluid: A good strategy in diagnosis of leptomeningeal metastases
Presenter: Yong Wang
Session: ePoster Display
1266P - Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets
Presenter: Hai-Yan Tu
Session: ePoster Display
1267P - Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy
Presenter: Mariona Riudavets Melia
Session: ePoster Display
1268P - Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
Presenter: Marta Garcia De Herreros
Session: ePoster Display